-
Key Considerations in Mediation Analysis for Psychiatric Research. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-23
Zui C Narita,Mitsuhiro Miyashita,Toshi A Furukawa,Atsuhi Nishida -
Distinct Convergent Brain Alterations in Sleep Disorders and Sleep Deprivation JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-23
Gerion M. Reimann, Alireza Hoseini, Mihrican Koçak, Melissa Beste, Vincent Küppers, Ivana Rosenzweig, David Elmenhorst, Gabriel Natan Pires, Angela R. Laird, Peter T. Fox, Kai Spiegelhalder, Kathrin Reetz, Simon B. Eickhoff, Veronika I. Müller, Masoud TahmasianImportanceSleep disorders have different etiologies yet share some nocturnal and daytime symptoms, suggesting common neurobiological substrates; healthy individuals undergoing experimental sleep deprivation also report analogous daytime symptoms. However, brain similarities and differences between long-term sleep disorders and short-term sleep deprivation are unclear.ObjectiveTo investigate the shared
-
Understanding Placebo Mechanisms to Reduce Attrition in Psychiatric Trials. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Nathan T M Huneke,Samuele Cortese,Marco Solmi -
Cognitive Behavior Therapy for Mental Disorders in Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Pim Cuijpers, Mathias Harrer, Clara Miguel, Marketa Ciharova, Davide Papola, Djordje Basic, Cristina Botella, Ioana Cristea, Nino de Ponti, Tara Donker, Ellen Driessen, Pamela Franco, Irene Gómez-Gómez, Jessica Hamblen, Noelia Jiménez-Orenga, Eirini Karyotaki, Aaron Keshen, Jake Linardon, Emma Motrico, Minoo Matbouriahi, Olga M. Panagiotopoulou, Rory A. Pfund, Constantin Yves Plessen, Heleen RiperImportanceCognitive behavior therapy (CBT) is a first-line treatment for most mental disorders. However, no meta-analytic study has yet integrated the results of randomized clinical trials on CBT across different disorders, using uniform methodologies and providing a complete overview of the field.ObjectiveTo examine the effect sizes of CBT for 4 anxiety disorders, 2 eating disorders, major depression
-
Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Samuel T. Wilkinson, Gerard SanacoraThis Viewpoint explores potential justifications underlying the US Food and Drug Administration (FDA)’s rejection of methylenedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder, including lack of blinding and issues around the integrity of relevant clinical trials.
-
Negative Effects During Placebo Treatment JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16
Tom Bschor, Josephine Unger, Lea Nagel, Guido Schwarzer, Christopher BaethgeImportanceAnalyzing effects within placebo groups allows for transdiagnostic comparisons, as placebo is the only substance systematically studied across all major psychiatric diagnoses. Recently, the study team meta-analytically showed that improvement under placebo varies across major psychiatric diagnoses. However, comprehensive transdiagnostic comparisons of negative effects under placebo (nocebo
-
Lessons Learned From Drug Decriminalization Remedies in British Columbia. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-14
John F Kelly -
Automating the Addiction Behaviors Checklist for Problematic Opioid Use Identification JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09
Angus H. Chatham, Eli D. Bradley, Vanessa Troiani, Donielle L. Beiler, Parker Christy, Lori Schirle, Sandra Sanchez-Roige, David C. Samuels, Alvin D. JefferyImportanceIndividuals whose chronic pain is managed with opioids are at high risk of developing an opioid use disorder. Electronic health records (EHR) allow large-scale studies to identify a continuum of problematic opioid use, including opioid use disorder. Traditionally, this is done through diagnostic codes, which are often unreliable and underused.ObjectiveTo determine whether regular expressions
-
Convergence of Cannabis and Psychosis on the Dopamine System JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09
Jessica Ahrens, Sabrina D. Ford, Betsy Schaefer, David Reese, Ali R. Khan, Philip Tibbo, Rachel Rabin, Clifford M. Cassidy, Lena PalaniyappanImportanceDespite evidence that individuals with a cannabis use disorder (CUD) are at elevated risk of psychosis and that the neurotransmitter dopamine has a role in psychosis, the mechanism linking cannabis use and psychosis remains unclear.ObjectiveTo use neuromelanin-sensitive magnetic resonance imaging (MRI), referred to as the neuromelanin-MRI signal, a practical, proxy measure of dopamine function
-
Clinician Suicide Risk Assessment for Prediction of Suicide Attempt in a Large Health Care System JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09
Kate H. Bentley, Chris J. Kennedy, Pratik N. Khadse, Jasmin R. Brooks Stephens, Emily M. Madsen, Matthew J. Flics, Hyunjoon Lee, Jordan W. Smoller, Taylor A. BurkeImportanceClinical practice guidelines recommend suicide risk screening and assessment across behavioral health settings. The predictive accuracy of real-world clinician assessments for stratifying patients by risk of future suicidal behavior, however, remains understudied.ObjectiveTo evaluate routine clinical suicide risk assessment for prospectively predicting suicide attempt.Design, Setting, and
-
Functional vs Structural Cortical Deficit Pattern Biomarkers for Major Depressive Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-04
Peter Kochunov, Bhim M. Adhikari, David Keator, Daniel Amen, Si Gao, Nicole R. Karcher, Demetrio Labate, Robert Azencott, Yewen Huang, Hussain Syed, Hongjie Ke, Paul M. Thompson, Danny J. J. Wang, Braxton D. Mitchell, Jessica A. Turner, Theo G.M. van Erp, Neda Jahanshad, Yizhou Ma, Xiaoming Du, William Burroughs, Shuo Chen, Tianzhou Ma, Jair C. Soares, L. Elliot HongImportanceMajor depressive disorder (MDD) is a severe mental illness characterized more by functional rather than structural brain abnormalities. The pattern of regional homogeneity (ReHo) deficits in MDD may relate to underlying regional hypoperfusion. Capturing this functional deficit pattern provides a brain pattern–based biomarker for MDD that is linked to the underlying pathophysiology.ObjectiveTo
-
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-04
Antonio Del Casale, Sara Spirito, Jan Francesco Arena, Saskia Preissner, Marina Borro, Giovanna Gentile, Martina Nicole Modesti, Robert Preissner, Stefano Ferracuti, Maurizio SimmacoImportanceTreatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations’ effectiveness in real-world settings is sparse.ObjectiveTo
-
Demographic Gaps and Digital Innovations in Therapy Trends. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Qiang Xie -
Refining Social Determinants of Suicide Risk Research. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Ping-I Lin,Nawar Nayeem,Erick Messias -
Demographic Gaps and Digital Innovations in Therapy Trends-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Mark Olfson -
Should Inflammation Be a Specifier for Major Depression in the DSM-6? JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Manish K. Jha, Marion Leboyer, Carmine M. Pariante, Andrew H. MillerThis Viewpoint discusses the opportunity to include inflammatory biomarkers as specifiers for major depression in the upcoming Sixth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-6).
-
Genetic Confounding in the Association Between Traumatic Brain Injury and Mental Disorder or Suicide JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02
Søren Dinesen Østergaard, Jessica Mundy, Alisha Silvia Mercedes Hall, Katherine L. MuslinerImportanceTraumatic brain injury is common and occurs across all ages. Observational studies have shown that traumatic brain injury is associated with a wide range of mental disorders and suicide. Whether these associations represent a causal effect is, however, difficult to establish, and confounding by genetic liability for mental disorder may play a substantial role.ObjectiveTo investigate whether
-
Caring for Patients With Severe Anorexia Nervosa—A Capacity Evaluation Cannot Save Us JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26
Emily G. Holmes, Jane A. Hartsock, Amy S. MartinThis Viewpoint discusses assessing decision-making capacity in patients with severe anorexia nervosa and why a multidisciplinary approach is preferred.
-
Prescription Stimulant Prescribing, Nonmedical Use, and Shortages JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26
Joshua P. Rising, Robert M. CaliffThis Viewpoint discusses developing better evidence about appropriate use of stimulants, understanding and reducing nonmedical use of these medications, and responding to shortages.
-
Effective Components of Collaborative Care for Depression in Primary Care: An Individual Participant Data Meta-Analysis. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26
Hannah Schillok,Jochen Gensichen,Maria Panagioti,Jane Gunn,Lukas Junker,Karoline Lukaschek,Caroline Jung-Sievers,Philipp Sterner,Lukas Kaupe,Tobias Dreischulte,Mohammed K Ali,Enric Aragonès,David B Bekelman,Birgit Herbeck Belnap,Robert M Carney,Lydia A Chwastiak,Peter A Coventry,Karina W Davidson,Maria L Ekstrand,Alison Flehr,Susan Fletcher,Lars P Hölzel,Klaas Huijbregts,Viswanathan Mohan,Vikram PatelImportance Collaborative care is a multicomponent intervention for patients with chronic disease in primary care. Previous meta-analyses have proven the effectiveness of collaborative care for depression; however, individual participant data (IPD) are needed to identify which components of the intervention are the principal drivers of this effect. Objective To assess which components of collaborative
-
Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-19
Pouya Ebrahimi, Juan Carlos Batlle, Aryan Ayati, M. Haisum Maqsood, Clarine Long, Constantine Tarabanis, Natalie McGowan, David T. Liebers, Gregory Laynor, Kaveh Hosseini, Sean P. HeffronImportanceBariatric surgery, once the criterion standard in obesity treatment, has a small but concerning association with increased suicidality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), originally developed to treat diabetes, now provide substantial efficacy in the treatment of obesity. However, concerns of risk of suicidality with these medicines have been raised.ObjectiveTo evaluate
-
Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-19
Beth Han, Christopher M. Jones, Nora D. Volkow, S. Michaela Rikard, Deborah Dowell, Emily B. Einstein, Gery P. Guy, Naomi Tomoyasu, Jean Ko, Grant Baldwin, Yngvild Olsen, Wilson M. ComptonImportanceStimulants are increasingly prescribed for US adults. Whether such prescribing is associated with misuse and prescription stimulant use disorder (PSUD) is less understood.ObjectivesTo examine (1) sex- and age-specific trends in the number of persons dispensed stimulants and trends in dispensed prescription stimulants by prescriber specialty in 2019 through 2022; (2) prevalence of misuse and
-
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-19
Lorenz Mueller, Joyce Santos de Jesus, Yasmin Schmid, Felix Müller, Anna Becker, Aaron Klaiber, Isabelle Straumann, Dino Luethi, Eline C. H. M. Haijen, Petra P. M. Hurks, Kim P. C. Kuypers, Matthias E. LiechtiImportanceMicrodosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD’s efficacy in reducing ADHD symptoms remains unknown.ObjectiveTo determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with
-
Addressing the Double Bind of Women's Anger After Trauma. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12
Olivia Metcalf,David Forbes -
Maternal Inflammatory Proteins in Pregnancy and Neurodevelopmental Disorders at Age 10 Years JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12
Tingting Wang, Parisa Mohammadzadeh, Jens Richardt Møllegaard Jepsen, Jonathan Thorsen, Julie Bøjstrup Rosenberg, Cecilie Koldbæk Lemvigh, Nicklas Brustad, Liang Chen, Mina Ali, Rebecca Vinding, Casper-Emil Tingskov Pedersen, María Hernández-Lorca, Birgitte Fagerlund, Birte Y. Glenthøj, Niels Bilenberg, Jakob Stokholm, Klaus Bønnelykke, Bo Chawes, Bjørn H. EbdrupIMPORTANCEMaternal inflammation during pregnancy has been associated with an increased risk of neurodevelopmental disorders (NDDs), such as attention-deficit/hyperactivity disorder (ADHD) and autism, and cognitive deficits in early childhood. However, little is known about the contributions of a wider range of inflammatory proteins to this risk.OBJECTIVETo determine whether maternal inflammatory proteins
-
Circulating Blood-Based Proteins in Psychopathology and Cognition JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12
Upasana Bhattacharyya, Jibin John, Max Lam, Jonah Fisher, Benjamin Sun, Denis Baird, Stephen Burgess, Chia-Yen Chen, Todd LenczImportancePeripheral (blood-based) biomarkers for psychiatric illness could benefit diagnosis and treatment, but research to date has typically been low throughput, and traditional case-control studies are subject to potential confounds of treatment and other exposures. Large-scale 2-sample mendelian randomization (MR) can examine the potentially causal impact of circulating proteins on neuropsychiatric
-
Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12
Nathan T. M. Huneke, Guilherme Fusetto Veronesi, Matthew Garner, David S. Baldwin, Samuele CorteseImportanceExpectancy effects are significant confounding factors in psychiatric randomized clinical trials (RCTs), potentially affecting the interpretation of study results. This narrative review is the first, to our knowledge, to explore the relationship between expectancy effects, compromised blinding integrity, and the effects of active treatment/placebo in psychiatric RCTs. Additionally, we present
-
Differences in Blood Leukocyte Subpopulations in Schizophrenia JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05
Leon Dudeck, Madeleine Nussbaumer, Thomas Nickl-Jockschat, Paul C. Guest, Henrik Dobrowolny, Gabriela Meyer-Lotz, Zhongming Zhao, Roland Jacobs, Kolja Schiltz, Brisa S. Fernandes, Johann SteinerImportanceThis study aims to provide robust evidence to support or challenge the immune hypothesis of schizophrenia.ObjectiveTo conduct a meta-analysis of reports on blood leukocyte subpopulations in schizophrenia vs healthy controls, examining disease- and treatment-related differences as well as potential confounders.Data SourcesSystematic database search for English and non-English peer-reviewed
-
Sports Gambling and Drinking Behaviors Over Time JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05
Joshua B. Grubbs, Alexander J. Connolly, Scott Graupensperger, Hyoun S. Kim, Shane W. KrausImportanceSports gambling has become one of the most accessible forms of gambling in the United States, and recent research suggests that sports gambling coupled with frequent alcohol use may have deleterious health consequences.ObjectiveTo examine the trajectories of sports gambling frequency and alcohol-related problems over time and the associations between these trajectories.Design, Setting, and
-
Evidence-Based Practicing in Mental Health JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05
Benjamin G. Druss, Nev JonesThis Viewpoint explores the shift from the process-oriented concept of evidence-based practicing toward the development and distribution of evidence-based practices within the sphere of mental health care.
-
Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05
Matheus Rassi F. Ramos, Stephan Goerigk, Valquiria Aparecida da Silva, Beatriz Araújo Cavendish, Bianca Silva Pinto, Cássio Henrique Gomide Papa, João Vitor Resende, Izio Klein, Adriana Munhoz Carneiro, Juliana Pereira de Sousa, Kallene Summer Moreira Vidal, Leandro da Costa Lane Valiengo, Lais B. Razza, Luana Marotti Aparício, Lisiane Martins, Lucas Borrione, Mariana Batista, Natasha Kouvalesk MoranImportanceIntermittent theta-burst stimulation (iTBS) is an established treatment for treatment-resistant depression (TRD). Sessions conducted more than once daily (ie, accelerated TBS [aTBS]) may enhance antidepressant effects. However, evidence is limited to small trials, and protocols are time-consuming and can require neuroimaging-based targeting.ObjectiveTo evaluate the efficacy and safety of
-
An Approach to Providing Timely Mental Health Services to Diverse Youth Populations JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-26
Srividya N. Iyer, Patricia Boksa, Ridha Joober, Jai Shah, Rebecca Fuhrer, Neil Andersson, Shalini Lal, Giuseppe D’Andrea, Nora Morrison, Valerie Noel, Daniel Rabouin, Tovah Cowan, Kathleen MacDonald, Mary Anne Levasseur, Feodor Poukhovski-Sheremetyev, Amal Abdel-Baki, Lacey Augustine, Kevin Friese, Isabelle Godin, Katherine Hay, Daphne Hutt-MacLeod, Vickie Plourde, Norma Rabbitskin, Paula Reaume-ZimmerImportanceAccessing mental health care is challenging for youths, especially those facing intersectional disadvantages, but whether enhancing youth services increases reach and timeliness has rarely been investigated. ACCESS Open Minds (ACCESS-OM) transformed services at urban, rural, and Indigenous sites in Canada using 5 principles (early identification, rapid access, appropriate care, no age-based
-
Genetic Correlates of Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-26
Bohan Xu, Katherine L. Forthman, Rayus Kuplicki, Jonathan Ahern, Robert Loughnan, Firas Naber, Wesley K. Thompson, Charles B. Nemeroff, Martin P. Paulus, Chun Chieh FanImportanceTreatment-resistant depression (TRD) is a major challenge in mental health, affecting a significant number of patients and leading to considerable burdens. The etiological factors contributing to TRD are complex and not fully understood.ObjectiveTo investigate the genetic factors associated with TRD using polygenic scores (PGS) across various traits and explore their potential role in the
-
National Incidence of Physician Suicide and Associated Features JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-26
Hirsh Makhija, Judy E. Davidson, Kelly C. Lee, Arianna Barnes, Amanda Choflet, Sidney ZisookImportancePrevious reports regarding comparative suicide incidence among US physicians vs nonphysicians have been inconclusive.ObjectiveTo estimate the national incidence of male and female physician suicide and analyze associated factors, comparing findings to the general population.Design, Setting, and ParticipantsThis retrospective cohort study investigated suicides among physicians and nonphysicians
-
Looking Back, Moving Forward—Reflecting on a Career in Psychiatric Research JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-26
Charles F. ReynoldsThe arc of my career has focused on the integration of clinical care, mentoring, and research, leading to meaningful research questions and intervention trials advancing the field. In this Special Communication, I first offer a brief synopsis of my work as an academic psychiatrist, highlighting mission, themes and publications, sponsors, and collaborators. I then discuss activities as a mentor, focusing
-
Native Hawaiian and Pacific Islander Data in Overdose Research. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-01
Nikki Kalani Apana,Megan Y Gimmen,Kekoa Taparra -
Predicting Diagnostic Progression to Schizophrenia or Bipolar Disorder via Machine Learning JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-19
Lasse Hansen, Martin Bernstorff, Kenneth Enevoldsen, Sara Kolding, Jakob Grøhn Damgaard, Erik Perfalk, Kristoffer Laigaard Nielbo, Andreas Aalkjær Danielsen, Søren Dinesen ØstergaardImportanceThe diagnosis of schizophrenia and bipolar disorder is often delayed several years despite illness typically emerging in late adolescence or early adulthood, which impedes initiation of targeted treatment.ObjectiveTo investigate whether machine learning models trained on routine clinical data from electronic health records (EHRs) can predict diagnostic progression to schizophrenia or bipolar
-
Strengthening Safeguards for Psychiatric Uses of Ketamine. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-01
Brian S Barnett,Roger D Weiss,Gerard Sanacora -
Searching the Brain for the Cause of Psychosis. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-01
Stephan Heckers -
Integrated Nicotine Replacement and Behavioral Support to Reduce Smoking in Opioid Agonist Therapy JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-12
Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Jan Tore Daltveit, Jørn Henrik Vold, Einar Furulund, Fatemeh Chalabianloo, Torgeir Gilje Lid, Lars Thore FadnesImportanceApproximately 85% of individuals receiving opioid agonist therapy for opioid dependence smoke tobacco. Despite the significant health risks associated with smoking-related diseases, there has been limited evaluation of smoking interventions tailored to this population.ObjectiveTo determine the effectiveness of an intervention combining nicotine replacement with brief behavioral support in
-
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-12
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, Georgios Kostantinis, Thomas A. Gilmore, Neil R. Sullivan, Amanda C. Tow, Sarah S. Dermody, Mark A. Prince, Robyn Jordan, Sherry A. McKee, Paul J. Fletcher, Eric D. Claus, Klara R. KleinImportancePreclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these findings.ObjectiveTo evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and craving in adults with alcohol use disorder (AUD)
-
Making Progress in Clinical Trials for Suicide Prevention JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-12
Samuel T. Wilkinson, Craig J. Bryan, Larry D. Alphs, Carla M. Canuso, Michael J. Ostacher, Rebecca B. Price, Michael H. Bloch, Carlos A. Zarate, Taeho Greg RheeImportanceSuicide is a public health crisis, and despite renewed efforts to confront this problem, suicide rates continue to rise in the US. While suicide prevention encompasses a broad array of strategies, treatment development is lagging. Within this realm, clinical trials are the criterion standard for evaluating safety and efficacy of new treatments.ObservationsMost clinical trials conducted among
-
Mapping Lesions That Cause Psychosis to a Human Brain Circuit and Proposed Stimulation Target JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-12
Andrew R. Pines, Summer B. Frandsen, William Drew, Garance M. Meyer, Calvin Howard, Stephan T. Palm, Frederic L. W. V. J. Schaper, Christopher Lin, Konstantin Butenko, Michael A. Ferguson, Maximilian U. Friedrich, Jordan H. Grafman, Ari D. Kappel, Clemens Neudorfer, Natalia S. Rost, Lauren L. Sanderson, Joseph J. Taylor, Ona Wu, Isaiah Kletenik, Jacob W. Vogel, Alexander L. Cohen, Andreas Horn, MichaelImportanceIdentifying anatomy causally involved in psychosis could inform therapeutic neuromodulation targets for schizophrenia.ObjectiveTo assess whether lesions that cause secondary psychosis have functional connections to a common brain circuit.Design, Setting, and ParticipantsThis case-control study mapped functional connections of published cases of lesions causing secondary psychosis compared
-
Effective Treatment for Mental and Substance Use Disorders in 21 Countries. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-01
Daniel V Vigo,Dan J Stein,Meredith G Harris,Alan E Kazdin,Maria Carmen Viana,Richard Munthali,Lonna Munro,Irving Hwang,Timothy L Kessler,Sophie M Manoukian,Nancy A Sampson,Ronald C Kessler,Importance Accurate baseline information about the proportion of people with mental disorders who receive effective treatment is required to assess the success of treatment quality improvement initiatives. Objective To examine the proportion of mental and substance use disorders receiving guideline-consistent treatment in multiple countries. Design, Setting, and Participants In this cross-sectional
-
Observational and Genetic Analyses of Traumatic Experiences and Endometriosis JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-05
Dora Koller, Solveig Løkhammer, Oksana Goroshchuk, Veronika Denner, Brendan Stiltner, Marina Mitjans, Jun He, Hugh S. Taylor, Rebecca B. Lawn, Karestan C. Koenen, Renato PolimantiImportanceAlthough psychological traumas have been associated with endometriosis, limited information is available regarding the role of trauma type and genetic predisposition.ObjectiveTo examine the relationship between traumatic experiences and endometriosis using observational and genetically informed analyses.Design, Setting, and ParticipantsFor this case-control study, the analyses were performed
-
An Opportunity to Advance Cannabis Science—DEA Rescheduling JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-05
Kevin P. Hill, Anshul V. PuliThis Viewpoint discusses the regulatory and financial barriers to cannabis research, and the potential changes to these barriers if cannabis is reclassified as a Schedule III drug.
-
Changes in Specialty Crisis Services Offered Before and After the Launch of the 988 Suicide and Crisis Lifeline JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-29
Jonathan Cantor, Megan S. Schuler, Rose Kerber, Jonathan Purtle, Ryan K. McBainImportanceThe launch of the 988 Suicide and Crisis Lifeline (988) in July 2022 aimed to enhance access to crisis mental health services by replacing the National Suicide Prevention Lifeline with a more memorable number and expanding the Lifeline scope beyond suicide. However, 988’s success relies on the availability of community crisis services.ObjectiveTo examine whether the launch of 988 was associated
-
Bright Light Therapy for Nonseasonal Depressive Disorders-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-01
Artur Menegaz de Almeida,Francisco Cezar Aquino Moraes,Francinny Alves Kelly -
Announcing "Technology and Psychiatry" and Expanding Evidence-Based Comments and Reviews in JAMA Psychiatry. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-01
Dost Öngür,Roy H Perlis -
Psychiatric, Neurological, and Somatic Comorbidities in Intermittent Explosive Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22
Yanli Zhang-James, John Paliakkara, Joshua Schaeffer, Joseph Strayhorn, Stephen V. FaraoneImportanceIntermittent explosive disorder (IED) is an understudied psychiatric condition marked by impulsive aggression and poorly regulated emotional control, often resulting in interpersonal and societal consequences. Better understanding of comorbidities can improve screening, diagnosis, and treatment.ObjectiveTo investigate the prevalence of IED and its associations with psychiatric, neurological
-
Medically Recommended vs Nonmedical Cannabis Use Among US Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22
Beth Han, Wilson M. Compton, Emily B. Einstein, Nora D. VolkowThis cross-sectional study assesses differences in cannabis use frequency and prevalence of cannabis use disorder between medical-only, medical-nonmedical, and nonmedical-only use among US adults.
-
Social Health and Serious Mental Illness—A Step Forward? JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-22
Jennifer Y. F. Lau, Stefan Priebe, Craig MorganThis Viewpoint discusses social health, which refers to the quality and quantity of social interactions, relationships, and support networks, as an important independent component of overall health alongside physical and mental health.
-
Employment Nondiscrimination Protection and Mental Health Among Sexual Minority Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-15
Michael Liu, Vishal R. Patel, Sahil Sandhu, Rishi K. Wadhera, Alex S. KeuroghlianImportanceIn the 2020 Bostock v Clayton County decision, the US Supreme Court extended employment nondiscrimination protection to sexual minority adults. The health impacts of this ruling and similar policies related to sexual orientation–based discrimination are not currently known.ObjectiveTo estimate changes in mental health following the Bostock decision among sexual minority adults in states that
-
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-08
Emanuel Boudriot, Marius Stephan, Finn Rabe, Lukasz Smigielski, Andrea Schmitt, Peter Falkai, Michael J. Ziller, Moritz J. Rossner, Philipp Homan, Sergi Papiol, Florian J. RaabeImportanceAs an accessible part of the central nervous system, the retina provides a unique window to study pathophysiological mechanisms of brain disorders in humans. Imaging and electrophysiological studies have revealed retinal alterations across several neuropsychiatric and neurological disorders, but it remains largely unclear which specific cell types and biological mechanisms are involved.ObjectiveTo
-
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-08
Michelle Matvey, D. Parker Kelley, Ellen R. Bradley, Winston Chiong, Aoife O’Donovan, Josh WoolleyImportanceThere is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment
-
What the Experiences of Young Persons Can Teach Us About Medical Aid in Dying for Psychiatric Illness. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-01
Brent Kious -
Requests for Medical Assistance in Dying by Young Dutch People With Psychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02
Lizanne J.S. Schweren, Sanne P.A. Rasing, Monique Kammeraat, Leah A. Middelkoop, Ruthie Werner, Saskia Y.M. Mérelle, Julian M. Garcia, Daan H.M. Creemers, Sisco M.P. van VeenImportanceIn the Netherlands, a growing group of young people request medical assistance in dying based on psychiatric suffering (MAID-PS). Little is known about this group, their characteristics, and outcomes.ObjectiveTo assess the proportion of requests for and deaths by MAID-PS among young patients, outcomes of their application and assessment procedures, and characteristics of those patients who
-
The Promise and Perils of Using Peers and Other Paraprofessionals as Mental Health Service Professionals JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02
Patricia A. Areán, Stephen O’Connor, Joel SherrillThis Viewpoint discusses better integration of peer support specialists and other paraprofessionals into clinical and community practice settings to help address the behavioral health workforce shortage.
-
Social Determinants of Health and Suicide-Related Outcomes JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02
Peter Jongho Na, Jeonghyun Shin, Ha Rim Kwak, Jaewon Lee, Dylan J. Jester, Piumee Bandara, Jim Yong Kim, Christine Y. Moutier, Robert H. Pietrzak, Maria A. Oquendo, Dilip V. JesteImportancePreventing suicide is one of the top priorities in public health policy. Identifying key social determinants of health (SDOH) in suicide risk is critical for informing clinical practices, future research, and policy solutions to prevent suicide.ObjectiveTo examine the associations of SDOH with suicide-related outcomes.Data SourcesStudies published before July 2023 were searched through PubMed
-
Left Ventrolateral Prefrontal Cortical Activity During Reward Expectancy and Mania Risk JAMA Psychiatry (IF 22.5) Pub Date : 2025-01-02
Manan Arora, Henry Chase, Michele A. Bertocci, Alexander S. Skeba, Kristen Eckstrand, Genna Bebko, Haris A. Aslam, Robert Raeder, Simona Graur, Osasumwen Benjamin, Yiming Wang, Richelle S. Stiffler, Mary L. PhillipsImportanceMania/hypomania is the pathognomonic feature of bipolar disorder (BD). As BD is often misdiagnosed as major depressive disorder (MDD), replicable neural markers of mania/hypomania risk are needed for earlier BD diagnosis and pathophysiological treatment development.ObjectiveTo replicate the previously reported positive association between left ventrolateral prefrontal cortex (vlPFC) activity